Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brittany Greenbaum

Otolaryngology Casper, WY Doctor of Osteopathy

NPI 1952793416 CMS profile 2237250

2210 King Blvd, Casper, WY 82604

Open in the dashboard

General payments

$1,094

21 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brittany Greenbaum of Casper, WY is reported in the CMS Open Payments database as having received $1,094 across 21 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 48th percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $104 2
2024 General $78 3
2023 General $132 2
2022 General $522 5
2021 General $44 3
2020 General $35 2
2019 General $179 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brittany Greenbaum
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to Brittany Greenbaum were reported at $104. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year Brittany Greenbaum Otolaryngology median Middle half National median
2019 $179 $194 $82–$512 $163
2020 $35 $118 $42–$280 $114
2021 $44 $167 $63–$444 $132
2022 $522 $216 $84–$545 $149
2023 $132 $235 $93–$588 $160
2024 $78 $280 $111–$699 $164
2025 $104 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Inspire Medical Systems, Inc. $684 5 payments
  2. Cochlear Americas $157 2 payments
  3. Regeneron Healthcare Solutions, Inc. $69 4 payments
  4. Aerin Medical Inc. $62 2 payments
  5. OptiNose US, Inc. $49 3 payments
  6. Genzyme Corporation $16 1 payment
  7. Smith+Nephew, Inc. $16 1 payment
  8. KCI USA, Inc $15 1 payment
  9. Integra LifeSciences Corporation $15 1 payment
  10. Medtronic, Inc. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $786 20 payments
  2. Travel and Lodging $308 1 payment
Products named General payments · program years 2019–2025
  1. Inspire Upper Airway Stimulation System $479 2 payments
  2. INSPIRE $205 3 payments
  3. Nucleus $135 1 payment
  4. Baha $135 1 payment
  5. DUPIXENT Inflammation And Immunology $69 4 payments
  6. DUPIXENT Immunology $64 4 payments
  7. VIVAER STYLUS $62 2 payments
  8. RHINAER STYLUS $62 2 payments
  9. Xhance $49 3 payments
  10. Cochlear Nucleus CI632 cochlear implant with Slim Modiolar electrode $22 1 payment
  11. Other $159 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

187

Median for Otolaryngology: 297

Drug cost

$2,679

Median for Otolaryngology: $6,314

Branded share of claims

27.3%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ipratropium Bromide Generic 26 $543
Ofloxacin Generic 13 $513
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 35 $474
Azelastine Hcl Generic 13 $383
Fluticasone Propionate Generic 14 $265
Pantoprazole Sodium Generic 24 $186
Mupirocin Generic 20 $141
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 16 $97
Famotidine Generic 26 $77

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 92 billing codes

Paid by Medicare

$128,742

Medicare's payments for the services billed

Medicare patients

518

Average age 74

Services billed

2,521

296 women, 222 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 41%
Diabetes 26%
Ischemic heart disease 22%
Depression 17%
Osteoporosis 17%
COPD 16%
Atrial fibrillation 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

21 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngology in Wyoming

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record